ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。

CRSP CRISPR Therapeutics AG

55.19
1.38 (2.56%)
取引時間後
最終更新日: 07:17:42
15分遅延
名称 銘柄コード 市場 種別
CRISPR Therapeutics AG CRSP NASDAQ 普通株式
  前日比 前日比 % 現在値 時刻
1.38 2.56% 55.19 07:17:42
始値 安値 高値 終値 前日終値
54.48 54.00 55.34 55.07 53.81
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/4/2305:30GLOBECRISPR Therapeutics to Present Oral Presentation at the..
2024/4/0321:00GLOBECRISPR Therapeutics to Present at the Annual Needham Virtual..
2024/4/0121:00GLOBECRISPR Therapeutics to Present at the American Society of..
2024/3/1321:30GLOBECRISPR Therapeutics Proposes New Appointment to the Board of..
2024/2/2207:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/2207:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/2121:50EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
2024/2/2121:45EDGAR2Form 8-K - Current report
2024/2/2121:30GLOBECRISPR Therapeutics Provides Business Update and Reports..
2024/2/1707:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/1606:30EDGAR2Form 144 - Report of proposed sale of securities
2024/2/1522:30GLOBECRISPR Therapeutics to Present at the Citi 2024 Virtual..
2024/2/1322:44EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
2024/2/1322:30GLOBECRISPR Therapeutics Announces $280 Million Registered Direct..
2024/2/1320:30EDGAR2Form 8-K - Current report
2024/2/1316:30GLOBEEuropean Commission Approves First CRISPR/Cas9 Gene-Edited..
2024/2/0107:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/3006:08EDGAR2Form 144 - Report of proposed sale of securities
2024/1/3006:00EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2024/1/1907:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/1707:00EDGAR2Form 144 - Report of proposed sale of securities
2024/1/1706:11EDGAR2Form 8-K - Current report
2024/1/1706:01GLOBECRISPR Therapeutics Announces U.S. Food and Drug..
2024/1/1101:36EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2024/1/0821:00GLOBECRISPR Therapeutics Highlights Strategic Priorities and 2024..
2024/1/0322:30GLOBECRISPR Therapeutics to Present at the 42nd Annual J.P...
2023/12/2006:23EDGAR2Form 8-K - Current report
2023/12/1522:58EDGAR2Form 8-K - Current report
2023/12/1323:22EDGAR2Form 8-K - Current report
2023/12/0906:11DJNBluebird Bio Shares Slide 41% on Black-Box Label, Higher..
2023/12/0903:16EDGAR2Form 8-K - Current report
2023/12/0902:52BWVertex and CRISPR Therapeutics Announce US FDA Approval of..
2023/12/0901:46DJNCRISPR, Vertex Get FDA OK of Casgevy Gene Therapy in..
2023/12/0506:26EDGAR2Form 8-K - Current report
2023/12/0506:15GLOBECRISPR Therapeutics Announces Updates to Immuno-Oncology..
2023/11/1621:21EDGAR2Form 8-K - Current report
2023/11/1615:45BW Vertex and CRISPR Therapeutics Announce Authorization of..
2023/11/0706:42EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/0706:33EDGAR2Form 8-K - Current report
2023/11/0706:15GLOBECRISPR Therapeutics Provides Business Update and Reports..
2023/11/0619:01GLOBECRISPR Therapeutics Announces Preclinical Data at the..
2023/11/0119:29DJNCrispr Therapeutics Shares Rally Premarket After Favorable..
2023/11/0106:53GLOBECRISPR Therapeutics Announces Completion of FDA Advisory..
2023/10/3120:05GLOBECRISPR Therapeutics Trading Halted Today; FDA Advisory..
2023/10/1806:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/10/1806:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/10/1806:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/10/1806:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/10/1621:00GLOBECRISPR Therapeutics Proposes New Appointment to the Board of..
2023/9/2722:01GLOBECRISPR Therapeutics to Present at the Society for..

最近閲覧した銘柄

Delayed Upgrade Clock